SANOFI-AVENTIS (EPA:SAN) New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia

Transparency directive : regulatory news

11/06/2021 09:00


Other stories

16/06/2021 10:10
16/06/2021 10:05
16/06/2021 05:27
16/06/2021 08:25
16/06/2021 02:41
15/06/2021 23:39
16/06/2021 01:00
15/06/2021 18:51
15/06/2021 21:14
16/06/2021 09:32
15/06/2021 13:40
16/06/2021 08:10
16/06/2021 00:18
15/06/2021 16:02
16/06/2021 09:13
16/06/2021 07:02
15/06/2021 23:05
16/06/2021 09:00
16/06/2021 00:14
15/06/2021 19:19
16/06/2021 06:50
16/06/2021 00:05
16/06/2021 01:16
16/06/2021 05:21
16/06/2021 07:20
16/06/2021 04:20
16/06/2021 08:06
16/06/2021 07:34
15/06/2021 23:14
15/06/2021 19:55
15/06/2021 05:35
15/06/2021 15:39
15/06/2021 22:12
15/06/2021 17:01
16/06/2021 01:03
15/06/2021 16:16
16/06/2021 00:26
15/06/2021 19:00